INN (Trade Name) Target Indication RoA Dose strength Mode of delivery
Erenumab (Alimovig®) CGRP receptor Migraines SC 70 or 140 mg/ml PFS, SureClick AI
Sarilumab (Kevzara®)
IL-6 receptor
Rheumatoid arthritis
SC
150 mg/1.14 ml, 200 mg/1.14 ml
PFS, pre-filled pen
Emicizumab (Hemlibra®) Factor IXa / X Haemophilia A SC 30 mg/ml, 150 mg/ml Injection, IV solution vial
Denosumab (Prolia®)
RANK-L
Postmenopausal osteoporosis
SC
Prolia: 60 mg/ml Xgeva: 70 mg/ml
PFS or vial
Adalimumab (Humira®) TNF-α Rheumatoid arthritis SC 40-80 mg/0.8 ml PFS, pre-filled pen or vial
Trastuzumab (Herceptin®)
HER2
Breast cancer
IV/SC
IV: 150 mg/single-dose vial, 400 mg/ multi-dose vial SC: (120mg/2000units)/ml IV: lyophilized powder SC: single-dose vial
Rituximab (Mabthera) CD20 Non-Hodgkin’s lymphoma IV/SC IV:10 mg/ml (10 and 50 ml vials) Single-dose vial
Teprotumumab (Tepezza®) Thyroid eye disease IV 500 mg/single-dose vial Lyophilized powder
Belimumab (Benlysta®)
BLyS
Systemic lupus erythematosus
IV/SC
IV: 120 or 400 mg/vial SC: 200 mg/ml IV: lyophilized powder SC: PFS or AI
Palivizumab (Synagis®) RSV Respiratory syncytial virus IM 100 mg/ml Powder for reconstitution (injection)
Muromonab (OKT3) (discontinued) CD3 Transplantation rejection IVP 1 mg/ml Injectable solution
Gemtuzumab (Mylotarg®) (discontinued) CD33 Acute myeloid leukaemia (AML) IV 4.5 mg/ml Single-dose vial